Evaluation of Reference variability [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2009-04-17 13:44 (4183 d 15:23 ago) – Posting: # 3555
Views: 2,549

Dear Nirali,

I agree with Ohlbe. Same opinions were expressed at the EUFEPS meeting last January (see this thread), where almost the entire PK group of EMEA was present. The group univocally expressed their point of view that a two period replicate design (reference only) is not acceptable. See also Jan Welink's presentation (slide 22).
On the other hand I know of European companies running such studies right now (despite clear reservations by regulators). Obviously these companies are sure that they will be able to convince authorities that the performance was not sloppy. I would not bet on their success!

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,086 posts in 4,398 threads, 1,468 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 05:08 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz